News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

First-line capivasertib-paclitaxel therapy misses survival target in metastatic TNBC
12 May 2026
byStephen Padilla
Combination treatment with capivasertib and paclitaxel falls short of prolonging overall survival (OS) compared with placebo plus paclitaxel in patients with metastatic triple-negative breast cancer (TNBC), either in the overall or PIK3CA/AKT1/PTEN-altered populations, as shown in the CAPItello-290 trial








